Abattis Biologix Corporation

CNSX : FLU


Abattis Biologix Corporation

March 19, 2012 08:00 ET

Abattis Closes on the Acquisition of Animo Wellness Corporation

Highlights:

- Definitive share exchange agreement for acquisition is closed

- Acquisition includes 75 Canadian licenses and NPN numbers issued by Health Canada

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 19, 2012) - Abattis Biologix Corporation (the "Company" or "Abattis") (CNSX:FLU) is pleased to announce that, further to its news release of March 13, 2012, the Company has closed the definitive share exchange agreement (the "Agreement") with Animo Wellness Corporation ("Animo") and its shareholders for the Company's acquisition of 100% of the outstanding shares of Animo (the "Transaction"). The closing of this transaction is March 16, 2012.

"We are pleased to close this transaction in a timely manner. This is the first of the previously announced acquisitions to close. The ownership of over 75 Canadian licenses and NPN numbers is yet again evidence that we continue to consistently deliver on our strategic plan while preparing for the commercial launch of our products, we are excited to be authorized for the sale of product in the market and to offer private label product orders and fulfill demand for the Health Canada licensed products. We expect this strategic acquisition to pave the way to Abattis' initial revenue this year," reports Mike Withrow, Chief Executive Officer of Abattis Biologix Corp.

About Animo Wellness Corporation

Animo is a wholly-owned subsidiary of Abattis Biologix Corp. The company holds over 75 natural health product licenses "NPNs" issued by Health Canada. The portfolio of these product licenses range from A- Aloe Vera to Z- Zinc.

About Abattis Biologix Corporation

Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The Company has identified targeted channels to market and license proprietary patent pending products throughout the world.

ON BEHALF OF THE COMPANY

Mike Withrow, Director

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

Contact Information